{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:41:28Z","timestamp":1793936488050,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["75N93021C00015"],"award-info":[{"award-number":["75N93021C00015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI08686"],"award-info":[{"award-number":["R01AI08686"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI126899"],"award-info":[{"award-number":["R01AI126899"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>mRNA lipid nanoparticle (LNP) vaccines would be useful during an influenza virus pandemic since they can be produced rapidly and do not require the generation of egg-adapted vaccine seed stocks. Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. Here, we generate an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b H5 isolate. The H5 mRNA-LNP vaccine elicits strong T cell and antibody responses in female mice, including neutralizing antibodies and broadly-reactive anti-HA stalk antibodies. The H5 mRNA-LNP vaccine elicits antibodies at similar levels compared to whole inactivated vaccines in female mice with and without prior H1N1 exposures. Finally, we find that the H5 mRNA-LNP vaccine is immunogenic in male ferrets and prevents morbidity and mortality of animals following 2.3.4.4b H5N1 challenge. Together, our data demonstrate that a monovalent mRNA-LNP vaccine expressing 2.3.4.4b H5 is immunogenic and protective in pre-clinical animal models.<\/jats:p>","DOI":"10.1038\/s41467-024-48555-z","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:01:55Z","timestamp":1716444115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus"],"prefix":"10.1038","volume":"15","author":[{"given":"Colleen","family":"Furey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-4791","authenticated-orcid":false,"given":"Gabrielle","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6232-8570","authenticated-orcid":false,"given":"Naiqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-0452","authenticated-orcid":false,"given":"Lisa","family":"Kercher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeBeauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeri Carol","family":"Crumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trushar","family":"Jeevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-4337","authenticated-orcid":false,"given":"Christopher","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rubrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-6930","authenticated-orcid":false,"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H. Y.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-1428","authenticated-orcid":false,"given":"Christopher A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-7132","authenticated-orcid":false,"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-7506","authenticated-orcid":false,"given":"Scott E.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"48555_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1750-2659.2011.00298.x","volume":"6","author":"Group, W. O. F. H. N. E. W.","year":"2012","unstructured":"Group, W. O. F. H. N. E. W. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respiratory Viruses 6, 1\u20135 (2012).","journal-title":"Influenza Other Respiratory Viruses"},{"key":"48555_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/22221751.2021.1872355","volume":"10","author":"NS Lewis","year":"2021","unstructured":"Lewis, N. S. et al. Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020. Emerg. Microbes Infect. 10, 148\u2013151 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"48555_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/v13020212","volume":"13","author":"JH Verhagen","year":"2021","unstructured":"Verhagen, J. H., Fouchier, R. A. M. & Lewis, N. Highly pathogenic avian influenza viruses at the wild\u2013domestic bird interface in Europe: future directions for research and surveillance. Viruses 13, 212 (2021).","journal-title":"Viruses"},{"key":"48555_CR4","doi-asserted-by":"crossref","unstructured":"Global Consortium for, H. N. & Related Influenza Viruses. Role for migratory wild birds in the global spread of avian influenza H5N8. Science 354, 213\u2013217 (2016).","DOI":"10.1126\/science.aaf8852"},{"key":"48555_CR5","doi-asserted-by":"publisher","first-page":"20814","DOI":"10.1073\/pnas.2001813117","volume":"117","author":"SJ Lycett","year":"2020","unstructured":"Lycett, S. J. et al. Genesis and spread of multiple reassortants during the 2016\/2017 H5 avian influenza epidemic in Eurasia. Proc. Natl Acad. Sci. USA 117, 20814\u201320825 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"48555_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13447-z","volume":"12","author":"V Caliendo","year":"2022","unstructured":"Caliendo, V. et al. Transatlantic spread of highly pathogenic avian influenza H5N1 by wild birds from Europe to North America in 2021. Sci. Rep. 12, 11729 (2022).","journal-title":"Sci. Rep."},{"key":"48555_CR7","doi-asserted-by":"publisher","first-page":"veac035","DOI":"10.1093\/ve\/veac035","volume":"8","author":"J King","year":"2022","unstructured":"King, J. et al. Highly pathogenic avian influenza virus incursions of subtype H5N8, H5N5, H5N1, H5N4, and H5N3 in Germany during 2020-21. Virus Evol. 8, veac035 (2022).","journal-title":"Virus Evol."},{"key":"48555_CR8","volume":"21","author":"C Adlhoch","year":"2023","unstructured":"Adlhoch, C. et al. Avian influenza overview December 2022 - March 2023. EFSA J. 21, e07917 (2023).","journal-title":"EFSA J."},{"key":"48555_CR9","volume":"20","author":"EFS Authority","year":"2022","unstructured":"Authority, E. F. S. et al. Avian influenza overview May \u2013 September 2021. EFSA J. 20, e07122 (2022).","journal-title":"EFSA J."},{"key":"48555_CR10","unstructured":"High pathogenicity avian influenza (HPAI)- situation report, 12 February 2022. (World Organisation for Animal Health-World Animal Health Information System, 2022)."},{"key":"48555_CR11","first-page":"e07415","volume":"20","author":"European Food Safety, A.","year":"2022","unstructured":"European Food Safety, A. et al. Avian influenza overview March - June 2022. EFSA J. 20, e07415 (2022).","journal-title":"EFSA J."},{"key":"48555_CR12","unstructured":"FAO-UN. Global Avian Influenza Viruses with Zoonotic Potential situation update, 25 April 2024 https:\/\/www.fao.org\/animal-health\/situation-updates\/ (2024)."},{"key":"48555_CR13","doi-asserted-by":"publisher","first-page":"e02867","DOI":"10.1128\/spectrum.02867-22","volume":"11","author":"L Bordes","year":"2023","unstructured":"Bordes, L. et al. Highly pathogenic avian influenza H5N1 virus infections in wild red foxes (Vulpes vulpes) show neurotropism and adaptive virus mutations. Microbiol Spectr. 11, e02867\u201302822 (2023).","journal-title":"Microbiol Spectr."},{"key":"48555_CR14","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.3201\/eid2711.211281","volume":"27","author":"JM Rijks","year":"2021","unstructured":"Rijks, J. M. et al. Highly pathogenic avian influenza A(H5N1) virus in wild red foxes, the Netherlands, 2021. Emerg. Infect. Dis. 27, 2960\u20132962 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"48555_CR15","doi-asserted-by":"crossref","unstructured":"Puryear, W. et al. Highly Pathogenic Avian Influenza A(H5N1) virus outbreak in New England Seals, United States. Emerg. Infect. Dis. 29, 786\u2013791 (2023).","DOI":"10.3201\/eid2904.221538"},{"key":"48555_CR16","doi-asserted-by":"publisher","first-page":"2100439","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100439","volume":"26","author":"OG Pyankova","year":"2021","unstructured":"Pyankova, O. G. et al. Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic avian influenza virus, from a worker during an outbreak on a poultry farm, Russia, December 2020. Euro. Surveill. 26, 2100439 (2021).","journal-title":"Euro. Surveill."},{"key":"48555_CR17","doi-asserted-by":"publisher","first-page":"2300001","DOI":"10.2807\/1560-7917.ES.2023.28.3.2300001","volume":"28","author":"M Ag\u00fcero","year":"2023","unstructured":"Ag\u00fcero, M. et al. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022. Euro. Surveill. 28, 2300001 (2023).","journal-title":"Euro. Surveill."},{"key":"48555_CR18","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3201\/eid2711.211225","volume":"27","author":"T Floyd","year":"2021","unstructured":"Floyd, T. et al. Encephalitis and death in wild mammals at a rehabilitation center after infection with highly pathogenic avian influenza A(H5N8) virus, United Kingdom. Emerg. Infect. Dis. 27, 2856 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"48555_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/22221751.2022.2043726","volume":"11","author":"A Postel","year":"2022","unstructured":"Postel, A. et al. Infections with highly pathogenic avian influenza A virus (HPAIV) H5N8 in harbor seals at the German North Sea coast, 2021. Emerg. Microbes Infect. 11, 725\u2013729 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"48555_CR20","doi-asserted-by":"publisher","first-page":"2186608","DOI":"10.1080\/22221751.2023.2186608","volume":"12","author":"TN Alkie","year":"2023","unstructured":"Alkie, T. N. et al. Characterization of neurotropic HPAI H5N1 viruses with novel genome constellations and mammalian adaptive mutations in free-living mesocarnivores in Canada. Emerg. Microbes Infect. 12, 2186608 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"48555_CR21","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326\u20133334 (2019).","journal-title":"Vaccine"},{"key":"48555_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"48555_CR23","doi-asserted-by":"publisher","first-page":"eaav5701","DOI":"10.1126\/scitranslmed.aav5701","volume":"12","author":"E Willis","year":"2020","unstructured":"Willis, E. et al. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci. Transl. Med. 12, eaav5701 (2020).","journal-title":"Sci. Transl. Med."},{"key":"48555_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"48555_CR25","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"48555_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2020.12.039","volume":"184","author":"EJ Topol","year":"2021","unstructured":"Topol, E. J. Messenger RNA vaccines against SARS-CoV-2. Cell 184, 1401 (2021).","journal-title":"Cell"},{"key":"48555_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38415-7","volume":"14","author":"A Kandeil","year":"2023","unstructured":"Kandeil, A. et al. Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America. Nat. Commun. 14, 3082 (2023).","journal-title":"Nat. Commun."},{"key":"48555_CR28","doi-asserted-by":"publisher","unstructured":"Neuzil, K. M. et al. Safety and immunogenicity of influenza A\/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac982 (2023).","DOI":"10.1093\/cid\/ciac982"},{"key":"48555_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01129-23","volume":"98","author":"H Li","year":"2024","unstructured":"Li, H. et al. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses. J. Virol. 98, e0112923 (2024).","journal-title":"J. Virol."},{"key":"48555_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/vaccines12020143","volume":"12","author":"NB Rudometova","year":"2024","unstructured":"Rudometova, N. B. et al. Immunogenic and protective properties of recombinant hemagglutinin of influenza A (H5N8) virus. Vaccines 12, 143 (2024).","journal-title":"Vaccines"},{"key":"48555_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/MAJ.0b013e3181e937b0","volume":"340","author":"MM Farley","year":"2010","unstructured":"Farley, M. M. 2009 H1N1 influenza: a twenty-first century pandemic with roots in the early twentieth century. Am. J. Med. Sci. 340, 202\u2013208, (2010).","journal-title":"Am. J. Med. Sci."},{"key":"48555_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","volume":"969","author":"N Pardi","year":"2013","unstructured":"Pardi, N., Muramatsu, H., Weissman, D. & Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969, 29\u201342 (2013).","journal-title":"Methods Mol. Biol."},{"key":"48555_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersdorfer","year":"2019","unstructured":"Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"48555_CR34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"48555_CR35","doi-asserted-by":"publisher","first-page":"15798","DOI":"10.1073\/pnas.1409171111","volume":"111","author":"SL Linderman","year":"2014","unstructured":"Linderman, S. L. et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc. Natl. Acad. Sci. USA 111, 15798\u201315803 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"48555_CR36","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1128\/JVI.03422-13","volume":"88","author":"JR Whittle","year":"2014","unstructured":"Whittle, J. R. et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J. Virol. 88, 4047\u20134057 (2014).","journal-title":"J. Virol."},{"key":"48555_CR37","doi-asserted-by":"publisher","first-page":"e1006271","DOI":"10.1371\/journal.ppat.1006271","volume":"13","author":"MB Doud","year":"2017","unstructured":"Doud, M. B., Hensley, S. E. & Bloom, J. D. Complete mapping of viral escape from neutralizing antibodies. PLOS Pathog. 13, e1006271 (2017).","journal-title":"PLOS Pathog."},{"key":"48555_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18465-x","volume":"11","author":"S Gouma","year":"2020","unstructured":"Gouma, S. et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat. Commun. 11, 4566 (2020).","journal-title":"Nat. Commun."},{"key":"48555_CR39","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/bioinformatics\/btw191","volume":"32","author":"G Monaco","year":"2016","unstructured":"Monaco, G. et al. flowAI: automatic and interactive anomaly discerning tools for flow cytometry data. Bioinformatics 32, 2473\u20132480 (2016).","journal-title":"Bioinformatics"},{"key":"48555_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48555-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:05:22Z","timestamp":1716444322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48555"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48555-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.30.538854","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.H. and D.W. are co-inventors on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and as a vaccine platform. S.E.H. reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. S.H.Y.F. is an employee of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4350"}}